Figure 3.

Treatment with MR16-1 decreased in the extent of atherosclerotic lesions in the mice aortas (en face) of both IκBNS^−/−/LDLr^−/− and LDLr^−/− mice. (A) Sudan IV staining of aortas from four groups after treatment of phosphate-buffered saline (PBS) or MR16-1 (2 mg) once a week during a high-fat diet consumption of 16 weeks (bars = 10 mm). (B) Quantitative analysis of the relative surface area of the atherosclerotic lesion in aortas. IκBNS/LDLr KO PBS: PBS-treated IκBNS^−/−/LDLr^−/− mice, LDLr KO PBS: PBS-treated LDLr^−/− mice. IκBNS/LDLr KO MR16-1: MR16-1-treated IκBNS^−/−/LDLr^−/− mice, LDLr KO MR16-1: MR16-1-treated LDLr^−/− mice. Data are expressed as mean ± SEM. *p < 0.05 and **p < 0.01. NS, not significant.